1 not yet recruiting, 1 recruiting, 1 terminated. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Riluzole (100 mg): new trials by email Literature Review of Riluzole (100 mg) trials Research Report on Riluzole (100 mg)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients Masitinib 4.5 mg/kg/day, Placebo, Riluzole (100 mg) - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Not yet recruiting | AB Science | 412 | 2026-01-01 | 2025-10-03 |
| PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Recruiting | PhenoNet, Inc. | 105 | 2025-11-25 | 2026-07-23 |
| Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS) Trametinib (0.5 mg), Trametinib (1 mg), Riluzole (100 mg) - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Terminated | Genuv Inc. | 23 | 2020-04-02 | 2023-05-09 |
Amyotrophic Lateral Sclerosis (3)
AB Science (1) · Genuv Inc. (1) · PhenoNet, Inc. (1)
Czechia (1) · Germany (1) · Greece (1) · Poland (1) · Serbia (1) · South Korea (1) · Spain (1) · United States (1)
Byoung Joon Kim (1)